<DOC>
	<DOCNO>NCT00684970</DOCNO>
	<brief_summary>Hamsa-1™ anti-angiogenic drug combination design treatment cancer . The investigational product Hamsa-1™ comprise four well-known active component . The therapy administrate unique dose regimen find effective advantageous term safety.The product formulate oral suspension , conveniently administrate patient home require medical staff assistance . This Phase IIb clinical trial aim evaluate efficacy Hamsa-1™ treatment metastatic Castration Resistant Prostate Cancer ( CRPC ) patient .</brief_summary>
	<brief_title>Phase IIB Clinical Trial Hamsa-1™ Metastatic Castration Resistant Prostate Cancer ( CRPC )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cimetidine</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . Subjects willing able give write informed consent 2 . Confirmed metastatic castration resistant prostate cancer rise PSA 3 . ECOG performance status ≤ 1 4 . Adequate renal function , hepatic function bone marrow reserve . 5 . Subjects capable swallow . 1 . Hypersensitivity one Hamsa1™ active component 2 . Glucose6phosphatedehydrogenase deficiency ( G6PD ) 3 . Subjects clinically significant unstable medical condition would preclude safe complete study participation 4 . Subjects receive investigational medication , antineoplastic therapy , significant change treatment within 1 month prior screen 5 . Subjects visceral metastasis ( e.g . liver , lung ) 6 . Subjects receive 2 prior chemotherapy treatment prostate cancer 7 . Subjects suffer circumstance likely interfere absorption orally administrate drug 8 . Subjects unwilling unable comply study protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>CRPC</keyword>
	<keyword>HRPC</keyword>
	<keyword>metastatic prostate cancer</keyword>
</DOC>